Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation
Page 1 of 1
Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation
Beigel JH, Voell J, Muñoz P, Kumar P, Brooks KM, Zhang J, Iversen P, Heald A, Wong M, Davey RT. Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation. Br J Clin Pharmacol. 2017 Sep 20. doi: 10.1111/bcp.13405. [Epub ahead of print]
Similar topics
» Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin activating protease TMPRSS2
» Quantitative determination of AVI-7100 (Radavirsen), a phosphorodiamidate morpholino oligomer (PMOplus®), in human plasma using LC-MS/MS
» Antisense morpholino targeting just upstream from a poly(A) tail junction of maternal mRNA removes the tail and inhibits translation
» Targeting protein translation, RNA splicing, and degradation by morpholino-based conjugates in Plasmodium falciparum
» Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy
» Quantitative determination of AVI-7100 (Radavirsen), a phosphorodiamidate morpholino oligomer (PMOplus®), in human plasma using LC-MS/MS
» Antisense morpholino targeting just upstream from a poly(A) tail junction of maternal mRNA removes the tail and inhibits translation
» Targeting protein translation, RNA splicing, and degradation by morpholino-based conjugates in Plasmodium falciparum
» Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum